The intraperitoneal injection of IL-31 in a murine breast cancer model resulted in CD8+ T-cell infiltration, which led to an immune response against tumor cells; better survival was also demonstrated due to the modulation of the release of cytokines like IL-10 and IL-2. Here, IL2 is linked to breast cancer.